1-ethyl-2-pyrrolidinylmethyl-alpha-phenylcyclopentylglycolate, 1-ethyl-3-piperidyl-alpha-phenylcyclopentylglycolate drug combination profile

The drug combination you described, **1-ethyl-2-pyrrolidinylmethyl-alpha-phenylcyclopentylglycolate and 1-ethyl-3-piperidyl-alpha-phenylcyclopentylglycolate**, is actually **not a known drug combination**. It's likely a hypothetical combination based on similar structures.

Here's why:

* **Individual Compounds:**
* **1-ethyl-2-pyrrolidinylmethyl-alpha-phenylcyclopentylglycolate:** This compound is very likely not a known drug. The chemical structure suggests a potential resemblance to anticholinergic drugs like scopolamine, which are used for motion sickness and other medical conditions. However, it's crucial to remember that chemical resemblance doesn't guarantee activity or even safety.
* **1-ethyl-3-piperidyl-alpha-phenylcyclopentylglycolate:** Similarly, this compound is also very likely not a known drug. Its structure resembles antihistamines and anticholinergics, but further investigation is needed to determine its potential pharmacological effects.

* **Importance for Research:**
* **Hypothetical Importance:** If you were to hypothesize about this combination's importance for research, you could argue that it could be interesting for studying:
* **Drug-drug interactions:** If these hypothetical compounds had similar targets (e.g., acetylcholine receptors) in the body, studying their combination could reveal potential synergistic effects or harmful interactions.
* **Structure-activity relationships:** Comparing the activity of these two compounds with subtle structural differences could be useful for understanding how small changes in molecular structure affect their pharmacological activity.

* **Caution:** **It's essential to emphasize that this is purely hypothetical, and without further research, it's impossible to know the true properties of these compounds or their potential combination.**

**Important Considerations:**

* **Drug Development:** The development of new drugs is a complex and lengthy process involving extensive preclinical and clinical testing to ensure safety and efficacy.
* **Ethical Concerns:** Research involving drug combinations should be conducted ethically, adhering to regulations and guidelines.
* **Scientific Literature:** If you're interested in exploring similar compounds or their potential therapeutic applications, consult peer-reviewed scientific publications and databases.

**If you're interested in learning more about drug development or the research of specific drug classes, I recommend exploring resources from organizations like the National Institutes of Health (NIH) or the Food and Drug Administration (FDA).**

1-ethyl-2-pyrrolidinylmethyl-alpha-phenylcyclopentylglycolate, 1-ethyl-3-piperidyl-alpha-phenylcyclopentylglycolate drug combination: contains 70% 1-ethyl-2-pyrrolidinylmethyl-alpha-phenylcyclopentylglycolate & 30% 1-ethyl-3-piperidyl-alpha-phenylcyclopentylglycolate [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	111040
MeSH ID	M0041880

Synonym
1-ethyl-3-piperidyl alpha-cyclopentyl-alpha-phenylglycolate hydrochloride
cs 62025
jb 329
cs 4298
us46xlx8yh ,
1-ethyl-2-pyrrolidinylmethyl-alpha-phenylcyclopentylglycolate - 1-ethyl-3-piperidyl-alpha-phenylcyclopentylglycolate
1-ethyl-2-pyrrolidinylmethyl-alpha-phenylcyclopentylglycolate, 1-ethyl-3-piperidyl-alpha-phenylcyclopentylglycolate drug combination
unii-us46xlx8yh
Q5283699
(1-ethylpyrrolidin-2-yl)methyl 2-cyclopentyl-2-hydroxy-2-phenylacetate;dihydrochloride

Excerpt	Relevance	Reference
" The present experiments extend these findings by providing dose-response data on the effects of scopolamine and Ditran on neocortical activity in relation to behavior in the rat."	( Joint cholinergic-serotonergic control of neocortical and hippocampal electrical activity in relation to behavior: effects of scopolamine, ditran, trifluoperazine and amphetamine. Stewart, DJ; Vanderwolf, CH, 1986)	0.27

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	15 (100.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (5.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	19 (95.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
indole [no description available]	3.03	1	indole; polycyclic heteroarene	Escherichia coli metabolite
mandelic acid SAMMA: mandelic acid condensation polymer	1.94	1	2-hydroxy monocarboxylic acid; benzenes	antibacterial agent; human xenobiotic metabolite
ketamine Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.. ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.	1.96	1	cyclohexanones; monochlorobenzenes; secondary amino compound	analgesic; environmental contaminant; intravenous anaesthetic; neurotoxin; NMDA receptor antagonist; xenobiotic
mescaline Mescaline: Hallucinogenic alkaloid isolated from the flowering heads (peyote) of Lophophora (formerly Anhalonium) williamsii, a Mexican cactus used in Indian religious rites and as an experimental psychotomimetic. Among its cellular effects are agonist actions at some types of serotonin receptors. It has no accepted therapeutic uses although it is legal for religious use by members of the Native American Church.. mescaline : A phenethylamine alkaloid that is phenethylamine substituted at positions 3, 4 and 5 by methoxy groups.	3.03	1	methoxybenzenes; phenethylamine alkaloid; primary amino compound	hallucinogen
neostigmine Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.. neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.	2.35	2	quaternary ammonium ion	antidote to curare poisoning; EC 3.1.1.7 (acetylcholinesterase) inhibitor
trifluoperazine [no description available]	1.96	1	N-alkylpiperazine; N-methylpiperazine; organofluorine compound; phenothiazines	antiemetic; calmodulin antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor; phenothiazine antipsychotic drug
lysergic acid diethylamide Lysergic Acid Diethylamide: Semisynthetic derivative of ergot (Claviceps purpurea). It has complex effects on serotonergic systems including antagonism at some peripheral serotonin receptors, both agonist and antagonist actions at central nervous system serotonin receptors, and possibly effects on serotonin turnover. It is a potent hallucinogen, but the mechanisms of that effect are not well understood.. lysergic acid diethylamide : An ergoline alkaloid arising from formal condensation of lysergic acid with diethylamine.	3.44	2	ergoline alkaloid; monocarboxylic acid amide; organic heterotetracyclic compound	dopamine agonist; hallucinogen; serotonergic agonist
dextroamphetamine Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.. (S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration.	1.96	1	1-phenylpropan-2-amine	adrenergic agent; adrenergic uptake inhibitor; dopamine uptake inhibitor; dopaminergic agent; neurotoxin; sympathomimetic agent
physostigmine Physostigmine: A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.	2.35	2	carbamate ester; indole alkaloid	antidote to curare poisoning; EC 3.1.1.8 (cholinesterase) inhibitor; miotic
phencyclidine Phencyclidine: A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to KETAMINE in structure and in many of its effects. Like ketamine, it can produce a dissociative state. It exerts its pharmacological action through inhibition of NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE). As a drug of abuse, it is known as PCP and Angel Dust.. phencyclidine : A member of the class of piperidines that is piperidine in which the nitrogen is substituted with a 1-phenylcyclohexyl group. Formerly used as an anaesthetic agent, it exhibits both hallucinogenic and neurotoxic effects.	3.45	2	benzenes; piperidines	anaesthetic; neurotoxin; NMDA receptor antagonist; psychotropic drug
acridines Acridines: Compounds that include the structure of acridine.. acridine : A polycyclic heteroarene that is anthracene in which one of the central CH groups is replaced by a nitrogen atom.	1.94	1	acridines; mancude organic heterotricyclic parent; polycyclic heteroarene	genotoxin
psilocybin Psilocybin: The major of two hallucinogenic components of Teonanacatl, the sacred mushroom of Mexico, the other component being psilocin. (From Merck Index, 11th ed). psilocybin : A tryptamine alkaloid that is N,N-dimethyltryptamine carrying an additional phosphoryloxy substituent at position 4. The major hallucinogenic alkaloid isolated from Psilocybe mushrooms (also known as Teonanacatl or "magic mushrooms").	1.93	1	organic phosphate; tertiary amino compound; tryptamine alkaloid	fungal metabolite; hallucinogen; prodrug; serotonergic agonist
atropine tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate : A tropane alkaloid that is (1R,5)-8-methyl-8-azabicyclo[3.2.1]octane substituted by a (3-hydroxy-2-phenylpropanoyl)oxy group at position 3.	2.34	2
scopolamine hydrobromide [no description available]	1.96	1
piperidines Piperidines: A family of hexahydropyridines.	5.12	15

Condition	Relationship Strength	Studies
Behavior Disorders [description not available]	2.85	4
Hallucination of Body Sensation [description not available]	1.93	1
Mental Disorders Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function.	2.85	4
Hallucinations Subjectively experienced sensations in the absence of an appropriate stimulus, but which are regarded by the individual as real. They may be of organic origin or associated with MENTAL DISORDERS.	1.93	1
Symptom Cluster [description not available]	1.93	1
Syndrome A characteristic symptom complex.	1.93	1
Antisocial Behavior Behavior that sharply deviates from social norms and violates rights of others	2.34	2
Affective Psychosis, Bipolar [description not available]	2.34	2
Psychoses [description not available]	2.63	3
Dementia Praecox [description not available]	3.54	3
Bipolar Disorder A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.	2.34	2
Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.	2.63	3
Psychotic Disorders Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994)	2.63	3
Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.	3.54	3
Anxiety Neuroses [description not available]	1.94	1
Psychoses, Alcoholic A group of mental disorders associated with organic brain damage and caused by poisoning from alcohol.	1.94	1
Anxiety Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.	1.94	1
Anxiety Disorders Persistent and disabling ANXIETY.	1.94	1
Coma A profound state of unconsciousness associated with depressed cerebral activity from which the individual cannot be aroused. Coma generally occurs when there is dysfunction or injury involving both cerebral hemispheres or the brain stem RETICULAR FORMATION.	1.93	1
Depression, Endogenous [description not available]	1.93	1
Depressive Disorder An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.	1.93	1

1-ethyl-2-pyrrolidinylmethyl-alpha-phenylcyclopentylglycolate, 1-ethyl-3-piperidyl-alpha-phenylcyclopentylglycolate drug combination

Description

Cross-References

Synonyms (10)

Research Excerpts

Dosage Studied

Research

Studies (15)

Market Indicators

Research Demand Index: 11.41

Study Types